AgeneBio secures ADDF grant for new approach to delaying onset of Alzheimer’s Dementia
AgeneBio is developing AGB101, a Phase-3 ready candidate targeting a large unserved aMCI patient population. If approved, AGB101 will be the first and only therapeutic that targets hippocampus